February
2, 2017
VIA
EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
100 F.
St., N.E.
Washington,
D.C. 20549
Attention: Amanda
Ravitz, Assistant Director
Re:
Request for
Acceleration of Effectiveness of Registration Statement on Form S-1
(File No. 333-213051) of Bionik Laboratories Corp. (the
“Registrant”)
Ladies
and Gentlemen:
Pursuant to
Rule 461 under the Securities Act of 1933, as amended,
the Registrant hereby requests that the effectiveness of the
above-captioned Registration Statement (the “Registration Statement”)
be accelerated so that such Registration Statement will become
effective on Friday, February 3, 2016, at 4:00 p.m., Eastern
Time, or as soon thereafter as practicable.
The
Registrant acknowledges that (i) should the Securities and
Exchange Commission (the “Commission”) or the
staff, acting pursuant to delegated authority, declare the filing
effective, it does not foreclose the Commission from taking any
action with respect to the filing, (ii) the action of the
Commission or the staff, acting pursuant to delegated authority, in
declaring the filing effective, does not relieve the Registrant
from its full responsibility for the adequacy and accuracy of the
disclosure in the filing, and (iii) the Registrant may not
assert the declaration of effectiveness as a defense in any
proceeding initiated by the Commission or any person under the
federal securities laws of the United States.
Please
call the undersigned at (416) 640-7887 x 508 with any questions
regarding this matter.
Very
truly yours,
BIONIK
LABORATORIES CORP.
By:
__/s/ Peter
Bloch__________________
Name:
Peter Bloch
Title:
Chairman and Chief Executive Officer